BioPharma Site Solutions Nexus to Focus on Overcoming Obstacles in Research Trial Site Management

October 14, 2024 08:05:00

Innovation in scientific research, that attempts to address some of the most challenging diseases of the modern era, depends largely on the biopharmaceuticals industry’s ability to establish and sustain viable clinical research trial sites.

Test research sites are often beset by difficulties ranging from high participant dropout rates to funding constraints. Clinical research managers are tasked with addressing stringent regulatory compliance, maintaining data integrity, and ensuring that research staff are adequately trained and supported to…

Read More>>

For more information about this event and to register, please visit https://ibn.fm/Kozo6.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN